Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

1559O Efficacy and toxicity of BNT162b2 vaccine in cancer patients

I. Ben-Aharon[1], I. Waldhorn[1], R. Holland[1], A. Peer[1], M. Halberthal[2], T.G. Goshen - Lago[1]

[1]Division of Oncology, Rambam Medical Center, Haifa, Israel; [2]General Management, Rambam Medical Center, Haifa, Israel

Background: Efficacy and safety profile of COVID-19 vaccines had been acquired from phase III studies. Nevertheless, cancer patients were not represented in these trials. In 1/2021 mass vaccination of high-risk population, including cancer patients, was initiated in Israel. We aimed to prospectively evaluate efficacy, immunogenicity and safety of BNT162b2 vaccine in cancer patients.

Methods: Cancer patients on active treatment were prospectively enrolled following first dose of BNT162b2 or after a second dose. Serum was collected after each dose and additionally in case of seronegativity. An age-matched cohort of healthcare workers served as controls. Questionnaires regarding sociodemographics and adverse reactions were employed at serum collection. FDA-approved assay was used to assess IgG at all time-points. Patients' electronic medical records were reviewed for documentation of COVID-19 infection, blood counts, liver enzymes and imaging studies.

Results: The study included 232 cancer patients and 261 controls. Following first dose 29% of patients were seropositive compared with 84% of controls ($p<0.001$). Following second dose seropositive rate reached 86%. Rate per 1000-person days after first dose were 12.5 for patients and 48.5 for controls. Chemotherapy reduced immunogenicity (OR 0.41 (95%CI 0.17-0.98). In seronegative patients, rate of documented leukopenia reached 39%. No COVID19 cases were documented throughout the study period except two cases following the first dose. Reported adverse events resembled former published studies.

Conclusions: Our results indicate the BNT162b2 appear to be safe and effective in cancer patients. There is a pronounced lag in antibody production compared with non-cancer controls, however seroconversion occurred in most patients after the second dose. Future real-world data is warranted to determine the long-term efficacy of the vaccine with regard to type of anti-cancer treatment.

Legal entity responsible for the study: The authors.

Funding: ICRF.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2021.08.1552

1560O Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection

A. Cortellini[1], E. Roldán[2], M.C. Carmona Garcia[3], R. Berardi[4], A. Sánchez[5], C. Martinez[6], A. Parisi[7], E. Jones[8], R.M. Bertulli[9], G. Rizzo[10], A. Guida[11], C. Chung[12], M.D. Bower[13], M. Betti[14], B. Vincenzi[15], O. Mirallas[16], F. Biello[17], P. Queirolo[18], A. Gennari[19], D.J. Pinato[20]

[1]Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; [2]Hematology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; [3]Medical Oncology Dept., Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain; [4]Clinical Oncology, Dept. of Internal Medicine, AOU - Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Torrette Di Ancona, Italy; [5]Medical Oncology, Hospital Universitario XII de Octubre, Madrid, Spain; [6]Medical Oncology, Fundació Althaia Manresa, Manresa, Spain; [7]Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy; [8]Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK; [9]Medical Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy; [10]Oncology Dept., Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; [11]Medical Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy; [12]Surgery and Cancer, Imperial College London, London, UK; [13]Medical Oncology, Chelsea and Westminster Hospital - NHS Trust, London, UK; [14]Infrastruttura Ricerca Formazione Innovazione, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; [15]Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy; [16]Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; [17]Medical Oncology, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy; [18]Melanoma and Sarcoma Medical Treatment Unit, IEO - Istituto Europeo di Oncologia, Milan, Italy; [19]Medical Oncology Department, Università degli Studi del Piemonte Orientale - Scuola di Medicina, Novara, Italy; [20]Surgery and Cancer, Imperial College London - Hammersmith Hospital, London, UK

Background: The long-term impact of COVID-19 in cancer patients (pts) is undefined.

Methods: Among 2795 consecutive pts with COVID-19 and cancer registered to OnCovid between 01/2020 and 02/2021, we examined clinical outcomes of pts reassessed post COVID-19 recovery.

Results: Among 1557 COVID-19 survivors, 234 (15%) reported sequelae including respiratory symptoms (49.6%), fatigue (41%) and cognitive/psychological dysfunction (4.3%). Persisting COVID-19 sequelae were more likely found in males ($p=0.0407$) aged $\geq$65 years ($p=0.0489$) with $\geq$2 comorbidities ($p=0.0006$) and positive smoking history ($p=0.0004$). Sequelae were associated with history of prior hospitalisation ($p<0.0001$), complicated disease ($p<0.0001$) and COVID-19 therapy ($p=0.0002$). With a median post-COVID-19 follow up of 128 days (95%CI 113-148), multivariable analysis of survival revealed COVID-19 sequelae to be associated with an increased risk of death (HR 1.76, 95%CI 1.16-2.66) after adjusting for sex, age, comorbidities, tumour characteristics, anticancer therapy and COVID-19 severity. Out of 473 patients who were on systemic anticancer therapy (SACT) at COVID-19 diagnosis; 62 (13.1%) permanently discontinued therapy and 75 (15.8%) received SACT adjustments, respectively. Discontinuations were due to worsening performance status (45.1%), disease progression (16.1%) and residual organ disfunction (6.3%). SACT adjustments were pursued to avoid hospital attendance (40%), prevent immunosuppression (57.3%) or adverse events (20.3%). Multivariable analyses showed permanent discontinuation to be associated with an increased risk of death (HR 4.2, 95%CI: 1.62-10.7), whereas SACT adjustments did not adversely affect survival.

Conclusions: Sequelae post-COVID-19 affect up to 15% of patients with cancer and adversely influence survival and oncological outcomes after recovery. SACT adjustments can be safely pursued to preserve oncological outcomes in patients who remain eligible to treatment.

Clinical trial identification: NCT04393974.

Legal entity responsible for the study: Imperial College London.

Funding: Has not received any funding.

Disclosure: A. Cortellini: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Advisory Board: Sun Pharma. D.J. Pinato: Financial Interests, Personal, Advisory Board: ViiV Healthcare; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2021.08.1553

1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series

K.H.J. Lim[1], K. Punie[2], C. Oing[3], E. Thorne[4], K. Murali[5], K.V. Kamposioras[6], M. O'Connor[7], E. Elez[8], T.M.S. Amaral[9], P. Garrido Lopez[10], M. Lambertini[11], B. Devnani[12], C.B. Westphalen[13], G. Morgan[14], J.B.A.G. Haanen[15], C. Hardy[4], S. Banerjee[16]

[1]Department of Immunology and Inflammation, Imperial College London & The Francis Crick Institute, London, UK; [2]Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; [3]Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, Mildred Scheel Cancer Career Centre HaTriCs4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; [4]Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK; [5]Victorian Clinical Genetics Services, The Royal Children's Hospital, Melbourne, VIC, Australia; [6]Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; [7]Medical Oncology Department, University Hospital Waterford, Waterford, Ireland; [8]Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; [9]Department of Dermatology, University Hospital Tübingen, Tübingen, Germany & Portuguese Air Force Health Care Direction, Lisbon, Portugal; [10]Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain; [11]Department of Medical Oncology and Department of Internal Medicine, IRCCS Ospedale Policlinico San Martino and University of Genoa, Genoa, Italy; [12]Department of Radiotherapy and Oncology, AIIMS - All India Institute of Medical Sciences, Jodhpur, India; [13]Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig Maximilian University of Munich, Munich, Germany; [14]Department of Medical and Radiation Oncology, Skane University Hospital, Lund, Sweden; [15]Division of Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, Netherlands; [16]Gynaecology Department, Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, UK

Background: The ESMO Resilience Task Force has investigated wellbeing since COVID-19 in relation to work, lifestyle and support factors in oncology professionals globally. We reported on the significant impact of the initial surge of the pandemic on wellbeing and job performance (Banerjee *et al.* 2021). As the pandemic continues, it is imperative to understand experiences and concerns to better inform support measures for the oncology workforce.

Methods: Three anonymous online surveys were conducted during the COVID-19 pandemic (S1, Apr/May 2020; S2, Jul/Aug 2020; S3, Feb/Mar 2021). Longitudinal analysis of responses at these timepoints were conducted. Here, we present responses to questions on job demands and resources, and perceived job performance since COVID-19 (JP-CV).

Results: We analysed 3894 individual responses (S1, n=1520; S2, n=942; S3, n=1432): 53% (n=1961/3731) female, 45% (n=1679/3731) =/<40 years, 31% (n=1132/3692) non-white ethnicity, >100 countries. There has been significant increases from S1 to S3 ($p<0.001$) in feeling overwhelmed with workload (29% vs 45%); COVID-19-related clinical (14% vs 58%) and research (16% vs 64%) work; out-of-hours work (16% vs 41%), shift work (12% vs 26%) and overall working hours (17% vs 47%); and inadequate time for personal/family life (35% vs 45%). 59% (n=1156/1946) were